AbCheck utilizes an unique combination of in vitro and in vivo technologies as sources for antibody discovery. We use libraries of human antibodies and project-specifically humanized libraries cloned from immunized rabbits to identify distinctive antibody sequences against our clients‘ targets. In a tailored workflow approach, AbCheck provides a seamless and sophisticated transition between phage and yeast display selection strategies. AbCheck provides various options for the de novo discovery of antibodies against virtually all targets in scFv, IgG or bi-specific formats. Our scientific expertise and technology platforms that have been refined and advanced over years, deliver a highly specific antibody for better outcomes.